Fig 7. ssAAV2-STC-1-FLAG reduces IOP by increasing outflow facility.

3-month-old C57BL/6J mice were randomized to receive either a single injection of intracameral ssAAV2-STC-1-FLAG (n = 5; 3x10⁹ VGs) or ssAAV2-GFP (n = 5; 3x10⁹ VGs) or daily topical STC-1-FLAG (n = 4), LFA (n = 5) or no treatment (n = 4) in one eye. IOP was measured, and aqueous humor dynamics was performed at maximal treatment response (week 6 for injection experiments and day 5 for topical experiments). A) IOP was significantly reduced in mice treated with intracameral ssAAV2-STC-1-FLAG, topical LFA, and topical STC-1-FLAG compared to intracameral ssAAV2-GFP. No significant difference was seen between untreated and ssAAV2-GFP-injected mice. B) Outflow facility was significantly increased in mice treated with intracameral ssAAV2-STC-1-FLAG, topical LFA, and topical STC-1-FLAG compared to intracameral ssAAV2-GFP. No significant difference was seen when comparing untreated and ssAAV2-GFP-injected mice. *P<0.05, ** P<0.01.